Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
SANTA MONICA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, being held March 20-21 at the Westin Grand Central Hotel in New York City.
Presentation Details | ||
Date: | Wednesday, March 21 | |
Time: | 1:00pm Eastern Time | |
Location: | Westin Grand Central Hotel, Track 3 | |
Webcast: | https://ir.opiant.com |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com.
CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 535-7746
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.